Journal article · 2025 · Open access

Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections

Lorena Bermúdez Barrezueta, Vanesa Matías del Pozo, José Manuel Marugán‐Miguelsanz, Elena Infante López, Pilar Uribe-Reina, Yara Romero del Hombrebueno, Antonio Jesús Morales-Moreno, Silvia Rojo‐Rello, José María Eirós Bouza, Asunción Pino Vázquez

European Journal of Pediatrics, 184(6), 345 · Published 15 May 2025 · DOI 10.1007/s00431-025-06125-5

Open PDFView at the publisherCite this paper

In brief

“Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections” is a 2025 journal article by Lorena Bermúdez Barrezueta and 9 co-authors, published in European Journal of Pediatrics. OpenAlex counts 7 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at European Journal of Pediatrics.

Citations
7
Most cited in
2026 (5)
Field-weighted impact
3.28
References
30
Authors
10

Abstract

The aim of this study was to assess the impact of universal nirsevimab administration on hospitalisations and paediatric intensive care unit (PICU) admissions due to lower respiratory tract infection associated with respiratory syncytial virus (RSV-LRTI). An observational study was conducted at a tertiary hospital in Spain to compare the frequency and characteristics of children under five years of age hospitalised for RSV-LRTI between October 2023 and March 2024 (nirsevimab period), with the data from two prepandemic COVID- 19 seasons (2018-2019 and 2019-2020) and one postpandemic season (2022-2023). A total of 311 patients were included in the study. During the nirsevimab period, a decrease in the number of children hospitalised for RSV-LRTI was observed, particularly for children under six months of age. Compared with the prepandemic period, there was an 83.3% decrease in hospitalisations and a 73.3% reduction in PICU admissions in this age group. Similarly, compared with the postpandemic period, there was a 90.8% reduction in hospitalisations and an 87.9% reduction in PICU admissions. Furthermore, the median age was greater (15.6 months; IQR 11.1-27.3) than it was in the prepandemic period (4 months; IQR 1.6-8.9) and postpandemic period (3.4 months; IQR 1.5-10.6) (p < 0.001). Moreover, the length of hospital stay during the nirsevimab period (4 days; IQR 3-6) was shorter than that observed during the prepandemic period (6 days; IQR 4-9) and the postpandemic period (5 days; IQR 3-8) (p = 0.003).Conclusions: Following the introduction of universal immunoprophylaxis with nirsevimab, notable reductions in hospitalisations and PICU admissions due to RSV-LRTI were observed among young infants. This resulted in a shift in the age profile and a shorter length of hospital stay. What Is Known • Nirsevimab is a novel humanised IgG1 monoclonal antibody with a prolonged half-life that has been demonstrated to reduce RSV-associated hospitalisations in controlled clinical trials; however, real-world data are still limited. What Is New: • The findings of the present study corroborate the effectiveness of nirsevimab. Following the implementation of universal immunoprophylaxis with nirsevimab, a notable reduction in hospitalisations and admissions to the paediatric intensive care unit for RSV-associated lower respiratory tract infections was observed, particularly among infants younger than 6 months, who have been the main target of this passive immunisation strategy. In addition, the patients admitted were older and the length of hospital stay was shorter.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Barrezueta, L. B., del Pozo, V. M., Marugán‐Miguelsanz, J. M., López, E. I., Uribe-Reina, P., del Hombrebueno, Y. R., Morales-Moreno, A. J., Rojo‐Rello, S., Bouza, J. M. E., & Vázquez, A. P. (2025). Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections. European Journal of Pediatrics, 184(6), 345. https://doi.org/10.1007/s00431-025-06125-5

MLA 9

Barrezueta, Lorena Bermúdez, et al. “Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections.” European Journal of Pediatrics, vol. 184, no. 6, 2025, p. 345. https://doi.org/10.1007/s00431-025-06125-5.

Chicago

Barrezueta, Lorena Bermúdez, Vanesa Matías del Pozo, José Manuel Marugán‐Miguelsanz, Elena Infante López, Pilar Uribe-Reina, Yara Romero del Hombrebueno, Antonio Jesús Morales-Moreno, Silvia Rojo‐Rello, José María Eirós Bouza, and Asunción Pino Vázquez. 2025. “Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections.” European Journal of Pediatrics 184 (6): 345. https://doi.org/10.1007/s00431-025-06125-5.

Harvard

Barrezueta, L. B. et al. (2025) ‘Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections’, European Journal of Pediatrics, 184(6), p. 345. doi:10.1007/s00431-025-06125-5.

IEEE

L. B. Barrezueta et al., “Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections,” European Journal of Pediatrics, vol. 184, no. 6, p. 345, 2025, doi: 10.1007/s00431-025-06125-5.

BibTeX

@article{barrezueta2025universal,
  title     = {{Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections}},
  author    = {Barrezueta, Lorena Bermúdez and del Pozo, Vanesa Matías and Marugán‐Miguelsanz, José Manuel and López, Elena Infante and Uribe-Reina, Pilar and del Hombrebueno, Yara Romero and Morales-Moreno, Antonio Jesús and Rojo‐Rello, Silvia and Bouza, José María Eirós and Vázquez, Asunción Pino},
  journal   = {European Journal of Pediatrics},
  year      = {2025},
  volume    = {184},
  number    = {6},
  pages     = {345},
  doi       = {10.1007/s00431-025-06125-5},
  url       = {https://doi.org/10.1007/s00431-025-06125-5}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Epidemiology › Respiratory viral infections research

  • nirsevimab
  • respiratory syncytial virus
  • infants
  • hospitalization
  • pediatric intensive care unit admission
  • length of hospital stay
  • monoclonal antibody prophylaxis
  • preterm infants

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Barrezueta, L. B., del Pozo, V. M., Marugán‐Miguelsanz, J. M., López, E. I., Uribe-Reina, P., del Hombrebueno, Y. R., Morales-Moreno, A. J., Rojo‐Rello, S., Bouza, J. M. E., & Vázquez, A. P. (2025). Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections. European Journal of Pediatrics, 184(6), 345. https://doi.org/10.1007/s00431-025-06125-5

How many times has this paper been cited?

7 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Journal of Pediatrics: sign in and open the PDF from this page.

Who wrote this paper?

Lorena Bermúdez Barrezueta, Vanesa Matías del Pozo, José Manuel Marugán‐Miguelsanz, Elena Infante López, Pilar Uribe-Reina, Yara Romero del Hombrebueno, Antonio Jesús Morales-Moreno, Silvia Rojo‐Rello, José María Eirós Bouza, Asunción Pino Vázquez.

What is the DOI of this paper?

10.1007/s00431-025-06125-5, permanently at https://doi.org/10.1007/s00431-025-06125-5. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.